Page last updated: 2024-11-07

3-amino-2-hydroxy-4-phenylbutanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID124913
SCHEMBL ID2201323
MeSH IDM0107370

Synonyms (19)

Synonym
beta-amino-alpha-hydroxybenzenebutanoic acid
3-amino-2-hydroxy-4-phenylbutyric acid
phenylnorstatine
benzenebutanoic acid, beta-amino-alpha-hydroxy-
3-amino-2-hydroxy-4-phenylbutanoic acid
allophenylnorstatine
62084-21-3
AKOS006305894
FT-0689801
MB02945
MB00533
LDSJMFGYNFIFRK-UHFFFAOYSA-N
SCHEMBL2201323
apns
FT-0771752
BCP05826
benzenebutanoic acid, beta-amino-alpha-hydroxy-, (r*,s*)- (9ci)
3-amino-2-hydroxy-4-phenylbutanoicacid
SY116580

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" administration, bioavailability of KNI-272 was 42."( Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere.
Kiso, Y, 1996
)
0.29
"11 microM) and showed good oral bioavailability in dogs."( Structure-activity relationship of HIV-1 protease inhibitors containing AHPBA. Part III: Modification of P2 site.
Iwamoto, A; Kasuya, A; Miyamoto, S; Nakagawa, A; Nishigaki, T; Nitta, T; Ozawa, Y; Shibayama, T; Takashiro, E; Watanabe, T; Yabe, Y; Yagi, R, 1998
)
0.3
" The present study demonstrated that JE-2147 has potent antiviral activities in vitro and exhibits good oral bioavailability and plasma pharmacokinetic profiles in two species of laboratory animals."( Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
Fukazawa, T; Hayashi, H; Kato, R; Kiso, Y; Mimoto, T; Misawa, S; Nojima, S; Sato, H; Shintani, M; Takaku, H; Terashima, K; Ueno, T, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (7.32)18.7374
1990's15 (36.59)18.2507
2000's18 (43.90)29.6817
2010's5 (12.20)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.16 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]